Dr. Janet Chollet

Dr. Janet A. Chollet is a board-certified obstetrician–gynecologist, biotechnology co-founder, and translational medicine leader based in Boston. She is the Co-Founder and Chief Medical Officer of Procyrn LLC, where she guides the development of sustained-release hydrogel immune therapeutics and reformulated antivirals. Her focus includes maternal–fetal health, neuroinflammation, and HPV-related cervical disease, areas where new solutions are urgently needed.

Janet Chollet MD, has over thirty years of experience in both clinical practice and academic medicine. Her career has included positions at major institutions in Boston and Pittsburgh, where she combined patient care with teaching and mentorship. Alongside her clinical work, she has contributed to innovation in women’s health by securing three U.S. patents related to drug delivery. She has been involved in advancing preclinical studies and early clinical programs, placing her work at the crossroads of patient needs and medical innovation.

Janet Chollet's education began with a Bachelor of Science in Neuroscience from a university in California in 1986. With a strong interest in connecting science to human health, she continued her studies in New York, where she earned her Doctor of Medicine degree in 1991. She then completed residency training in Obstetrics and Gynecology at a women’s hospital in Los Angeles between 1991 and 1995. These years of training shaped her commitment to improving care for women, children, and families.

After completing her residency, Dr. Janet Chollet joined a women’s hospital affiliated with a university in Pittsburgh as a staff physician and instructor. From 2000 to 2007, she combined teaching with patient care while developing her vision for translational medicine. In 2007, she moved to a leading Boston medical center, where she continues to practice as an obstetrician–gynecologist, contribute to academic training, and integrate her clinical experience with research.

In 2005, Dr. Chollet co-founded a pharmaceutical company dedicated to therapies for women’s health. Serving as Vice President of Clinical Affairs until 2018, she helped create drug delivery technologies aimed at women who could not use hormone-based therapies. Her efforts produced three U.S. patents, and the company later merged with a women’s health organization listed on the stock exchange.

In 2023, Dr. Janet co-founded Procyrn LLC, where she now leads clinical development, regulatory planning, and translational strategy. The company’s therapeutic programs include an effort to address preeclampsia and HELLP syndrome in pregnancy, an approach to neuroinflammation related to ALS, and a nonsurgical option for HPV-driven cervical disease. She has also encouraged exploratory research into maternal–fetal immune therapeutics as a way of reducing risks for neurodevelopmental disorders. She brings expertise in regulatory strategy, IND-enabling work, and careful planning of development milestones, ensuring progress is grounded in both scientific rigor and practical execution.

Earlier in her career, Dr. Chollet co-wrote an Emmy-winning episode of a medical television drama. Although invited to continue in that direction, she chose to remain in medicine, demonstrating her focus on patient care while also preserving her creative perspective.

Outside her professional work, she values family, wellness, and creative outlets. She maintains an exercise and strength training routine, enjoys golf for its balance and clarity, and appreciates travel, writing, and the companionship of pets. More recently, she has shown interest in the role of artificial intelligence in clinical workflows, seeing how technology can support advances in translational medicine.